HCV NS3 Genotype-1b
Description
Product Specs
Starts: MRDSDSQTFQ
Ends: DSVIDCNTCVT.
Product Science Overview
Hepatitis C Virus (HCV) is a significant global health concern, affecting millions of people worldwide. It is a small, enveloped virus with a positive-sense, single-stranded RNA genome. The virus encodes a large polyprotein that is processed into structural and non-structural proteins. Among these, the non-structural protein 3 (NS3) plays a crucial role in the virus’s life cycle and is a target for therapeutic interventions.
HCV is classified into several genotypes, with genotype 1 being the most prevalent and difficult to treat. Genotype 1b, in particular, is associated with a higher risk of developing liver cirrhosis and hepatocellular carcinoma. The NS3 protein of HCV genotype 1b is of significant interest due to its role in viral replication and its potential as a target for antiviral drugs.
The NS3 protein is a multifunctional enzyme with serine protease and RNA helicase activities. It is involved in the cleavage of the HCV polyprotein into functional units, which is essential for viral replication. The NS3 protein also interacts with host cell factors to modulate the immune response and promote viral persistence.
Recombinant NS3 proteins are produced using various expression systems to study their structure, function, and interactions with other viral and host proteins. These recombinant proteins are also used in the development of diagnostic assays and vaccines. For instance, the full-length recombinant NS3 of HCV genotype 1b has been expressed in different systems, including E. coli and mammalian cells, to facilitate research and therapeutic development .
- Diagnostics: Recombinant NS3 proteins are used in enzyme-linked immunosorbent assays (ELISA) and Western blot assays to detect HCV infection. These assays are highly specific and can differentiate between various HCV genotypes.
- Therapeutics: The NS3 protein is a target for direct-acting antiviral agents (DAAs). Inhibitors of the NS3 protease have been developed and are used in combination with other DAAs to achieve sustained virologic response in HCV-infected patients.
- Vaccines: Research is ongoing to develop vaccines that elicit robust immune responses against HCV. Recombinant NS3 proteins are being explored as potential vaccine candidates due to their immunogenic properties.
